United Therapeutics CEO executes 10b5-1 plan: 8,000 options exercised
Rhea-AI Filing Summary
United Therapeutics (UTHR) insider activity: Martine A. Rothblatt, Chairperson & CEO, executed a pre-arranged 10b5-1 plan and on 09/12/2025 and 09/15/2025 exercised stock options and sold shares. The filing shows two option exercises of 4,000 options each (total 8,000 options) at an exercise price of $120.26, resulting in acquisitions of 4,000 shares on each date. Concurrently, the reporting person sold 4,000 shares on 09/12/2025 and 4,000 shares on 09/15/2025 at weighted average prices in the low $400s, for total reported sales of 8,000 shares. The form discloses substantial additional holdings indirectly: trusts and spouse holdings totaling hundreds of thousands of shares and a tranche of 294,000 options expiring 03/15/2026 under the 10b5-1 plan.
Positive
- Transactions executed under a 10b5-1 plan, which provides pre-arranged, rule-compliant trading mechanics and reduces appearance of opportunistic insider timing.
- Exercised options at a low exercise price ($120.26), enabling liquidity while retaining substantial indirect holdings via trusts and spouse.
Negative
- Direct beneficial ownership decreased to 130 shares following the reported exercises and sales, showing a substantial reduction in personally held public shares.
- Significant sales at prices in the high $300s–$400s may be viewed by some investors as insider monetization of holdings.
Insights
TL;DR: CEO exercised options and sold shares under a pre-arranged 10b5-1 plan; large indirect holdings remain via trusts and spouse.
The transactions were executed under a documented 10b5-1 plan entered May 2, 2025, which governs exercise and sale timing and runs until tranche exhaustion or year-end. The filing shows option exercises at $120.26 and multiple market sales at weighted averages in the low $400s, consistent with routine liquidity events rather than opportunistic, unscheduled trades. Indirect beneficial ownership is significant, with trust and spouse holdings in the hundreds of thousands of shares and an outstanding option tranche of 294,000 options expiring 03/15/2026, which is material to total insider exposure.
TL;DR: Option exercises funded share sales under plan; net reported direct holdings decreased but sizable indirect positions persist.
The reporting person exercised 8,000 options (4,000 on each date) and sold 8,000 shares across the same dates at weighted average prices between $396.97 and $405.15 as disclosed. After these transactions, the filing lists direct beneficial ownership of 130 shares and substantial indirect holdings via spouse and multiple trusts. The continued existence of a large option tranche and trust-held shares indicates sustained economic exposure despite the executed sales.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 4,000 | $0.00 | -- |
| Exercise | Common Stock | 4,000 | $120.26 | $481K |
| Sale | Common Stock | 2,540 | $397.7086 | $1.01M |
| Sale | Common Stock | 1,460 | $398.1889 | $581K |
| Exercise | Stock Option | 4,000 | $0.00 | -- |
| Exercise | Common Stock | 4,000 | $120.26 | $481K |
| Sale | Common Stock | 1,000 | $402.21 | $402K |
| Sale | Common Stock | 1,000 | $403.91 | $404K |
| Sale | Common Stock | 2,000 | $404.89 | $810K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- This exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025. Thisplan will continue until the earlier of: (a) exhaustion of a tranche of 294,000 stock options that expire March 15, 2026; or (b) December 31, 2025. This transaction was executed in multiple trades at prices ranging from $402.21 to $403.2099. The price reported above reflects the weighted averageprice. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full informationregarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $403.405 to $404.4049. The price reported above reflects the weighted averageprice. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full informationregarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $404.62 to $405.15. The price reported above reflects the weighted averageprice. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full informationregarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $396.97 to $397.9699. The price reported above reflects the weighted averageprice. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full informationregarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $397.98 to $398.285. The price reported above reflects the weighted averageprice. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full informationregarding the number of shares and prices at which the transaction was effected. Shares held in family trusts as to which the Reporting Person shares investment power and the Reporting Person and/or immediate family members arebeneficiaries. Shares held in family trusts as to which the Reporting Person's spouse is sole trustee and sole beneficiary or co-trustee and settlor with power torevoke. Shares held in family trusts as to which the Reporting Person's spouse shares investment power and the Reporting Person and/or immediate familymembers are beneficiaries. Shares held in family trusts as to which the Reporting Person is sole trustee and sole beneficiary or co-trustee and settlor with power to revoke.
